Can mutation detection accurately predict XDR- TB: study from a tertiary care centre India
|
|
- Noel Jenkins
- 5 years ago
- Views:
Transcription
1 JCM Accepts, published online ahead of print on 2 February 2011 J. Clin. Microbiol. doi: /jcm Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Can mutation detection accurately predict XDR- TB: study from a tertiary care centre India Kanchan Ajbani, PhD student, Dept of Research, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, India Camilla Rodrigues, Consultant Microbiologist, Dept of Microbiology, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, India Shubhada Shenai, Dept of Research, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, India Ajita Mehta, Late* Consultant Microbiologist, Dept of Microbiology, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, India * Passed away on 6 th Feb Conflict of interest: There are no conflicts of interest for this manuscript. Kanchan Ajbani: No Conflict Camilla Rodrigues: No Conflict Shubhada Shenai: No Conflict
2 Source of financial support: The study was funded by National Health and Education Society, P. D. Hinduja National hospital and Medical Research Centre, Mumbai, India. Address for Correspondence Dr. Camilla Rodrigues Consultant Microbiologist, Dept of Microbiology, Research Laboratories, P. D. Hinduja National Hospital and Medical Research Centre; Veer Savarkar Marg, Mahim, Mumbai , India. Tel: Fax No.; address:
3 ABSTRACT We screened and spoligotyped 150 consecutive phenotypically confirmed XDR-TB isolates (Jan 08 to Mar 09) for rifampicin, isoniazid, fluoroquinolones and aminoglycoside resistance targeting rpob, inha, katg, gyra, gyrb and rrs. Mutations predominant amongst XDR- TB were 100% S315T (katg), 97% S531L (rpob), 53% D94G(gyrA), 71% A1401G(rrs). Spoligotyping revealed 62% to be Beijing. Key words: XDR-TB, fluoroquinolone, aminoglycoside. Running title: Extensively Drug Resistant tuberculosis
4 The worldwide emergence of Extensively Drug Resistant tuberculosis (XDR-TB) is a major setback to tuberculosis (TB) control (9, 11, 12, 15). XDR-TB, defined as Multi Drug Resistant (MDR) TB [i.e. resistant to rifampicin and isoniazid] with additional resistance to any fluoroquinolone (FQ) and to any one of three second line injectables i.e. capreomycin, kanamycin or amikacin (21). The mycobacteriology laboratory of P D Hinduja National Hospital (PDHNH), a tertiary care centre in central Mumbai received 7482 clinical specimens for TB culture using Mycobacterial Growth Indicator Tube (MGIT) and Lowenstein Jensen (L.J) from Jan Mar Our laboratory has a referral bias towards non responders as we receive mainly treatment failures and complicated TB cases and drug susceptibility testing (DST) is performed only on request samples were positive for Mycobacterium tuberculosis complex and 2522 patients requested DST of which 1640 (65%) were MDR and 150 (9.1%) were XDR-TB by MGIT (19). We studied mutations targeting the genes included in definition of XDR-TB [inha, katg, gyra (1, 5, 9, 14, 20, 27), gyrb and rrs (2, 16, 28)] and fingerprinted these patients isolates by spoligotyping (6). DNA extraction from pure culture was performed by the Cetyl trimethyl ammonium bromide (CTAB NaCl) method (23). A single tube touchdown multiplex PCR for three target genes associated with resistance to isoniazid (inha, katg) and rifampicin (rpob) was done and screened for mutations using an in House Reverse Line Blot Hybridisation (RLBH) assay (22). The screening of katg, resulted in the identification of G315C (100%) the S315T mutation in katg (Table 1) conferring high-level resistance to isoniazid with an altered catalase- peroxidase activity (24). 21(14%) of these isolates showed C-15T mutation in the promoter region of inha gene in addition to katg mutation. The promoter mutation was also seen among XDR-TB isolates in Portugal (18) and China (25). S531L mutation in rpob was more prevalent; observed in 146(97%) of these isolates, whereas H526Y mutation was observed only in 4 (3%) isolates. A
5 previous study from this centre (22) on MDR isolates revealed an array of point mutations from in rpob; however S531L in rpob mutation dominated among XDR-TB isolates. This is similar to a study from Portugal (18) where the S531L mutation dominated in XDR-TB Novel primers were designed to amplify a 350bp region of gyra, 550bp region for gyrb for fluoroquinolone resistance and 500bp region for rrs (codon ) for aminoglycoside resistance. The initial 50 amplified products were analyzed for bidirectional sequencing and after mutation confirmation, subsequent 100 products were sent for unidirectional sequencing (Chromous Biotech Pvt Ltd, Bangalore, India). DNA sequencing of gyra gene showed the presence of D94G mutation in 79 (53%) isolates phenotypically resistant to ofloxacin and moxifloxacin, whilst A90V mutation was observed in 37 (25%) isolates that were phenotypically sensitive to moxifloxacin but resistant to ofloxacin. This needs to be verified with Minimum Inhibitory Concentration (MIC) at higher drug concentrations for ofloxacin (13). The 94 th codon mutation D94G showed a high frequency i.e. 53% amongst our isolates. Other mutations at the 94 th codon D94A and D94N were found in 12% and 9% of isolates respectively. Other studies (25, 18) also show similar mutations in gyra. All isolates were sequenced for gyrb mutations but only one isolate phenotypically resistant to both ofloxacin and moxifloxacin showed a N510D mutation in gyrb in addition to D94G mutation in gyra. Sequencing of rrs gene revealed presence of A1401G mutation in 106 (71%) isolates that were phenotypically resistant to kanamycin and amikacin. Cross resistance between the two aminoglycosides kanamycin and amikacin is believed to exist (2, 16, 26, 28). 42 (28%) isolates phenotypically resistant to capreomycin in addition to kanamycin and amikacin showed presence of a G1484T mutation whereas other studies (18, 25) have reported several point mutations in rrs gene in addition to the 1401 and 1484 mutation.
6 For capreomycin resistant isolates, the tlya gene (17) that was split in two parts (tlya1 of 500bp and tlya2 of 300bp) was amplified using novel primers. The amplified products were sent for bidirectional sequencing. Of the 42 capreomycin resistant isolates sequenced for tlya in addition to rrs; 13 (31%) isolates showed A205G (K69E) and three isolates showed deletion of nucleotide T at 674 resulting in frameshift mutation. The remaining 26 isolates only showed G1484T mutation in the rrs with no tlya mutation. Two isolates that were phenotypically resistant to kanamycin, amikacin and capreomycin did not show any mutation in the rrs gene. This could be due to mutations in other hot spot regions that were not targeted in this study. Fingerprinting of all isolates was performed by spoligotyping (6) and the pattern was compared to an International Spoligotyping database (SpolDB4) (7, 29). Spoligotype pattern revealed that Beijing genotype was predominant among XDR-TB isolates that accounted for 62% of all the isolates followed by Central- Asian (CAS) (14%), T families i.e. T1 (13%), East- African- Indian (EAI) 5(7%) and EAI 3 (2%). There were three single isolates that each belonged to family 35 (assigned by Spotclust database which uses computer algorithm based on studies from SpolDB3 (10)), T4 and Haarlem genotype (Table 2). The sharing of a single spoligotype by 62% of isolates suggests an important role for transmission of a dominant resistant clone. Spoligotyping studies from Mumbai have shown other genotypes i.e. CAS and Manu1 to be predominant (4) whereas previous study from our centre (3) has reported high proportion of Beijing strains amongst resistant cases. However, results of the present study should not be over interpreted as sampling bias cannot be ruled out due to the non responders referred to our centre. Epidemiological associations between patients could not be ascertained as patients were not residents from the same locality or work place and 119/150 (79%) were on second line drugs for the duration of more than 1 year.
7 96 97 Thus mutational analysis could conclusively predict 100% resistance to isoniazid, rifampicin, fluoroquinolone and 98% for aminoglycosides amongst our XDR- TB cohort
8 114 ACKNOWLEDGEMENT: The study was funded by the National Health and Education Society, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai. India The authors have no potential conflict of interest relevant to the contents of this manuscript. The study has been approved by the Institutional Review Board of P. D. Hinduja National Hospital and Medical Research Centre, Mumbai. India
9 135 REFERECES: Alangaden G, Manavathu E, Vakulenko S, Zvonok N, Lerner S Characterization of fluoroquinolone resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrobial agents and Chemotherapy. 39: Alangaden G, Kreiswirth B, Aouad A, et al Mechanism of resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis. Antimicrobial agents and Chemotherapy. 42: Almeida, D., C. Rodrigues, T. F. Ashavaid, A. Lalvani, Z. F. Udwadia, and A. Mehta High incidence of the Beijing genotype among multidrugresistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India. Clin. Infect. Dis. 40: Arora, J., U. B. Singh, N. Suresh, T. Rana, C. Porwal, A. Kaushik, and J. N. Pande Characterization of predominant Mycobacterium tuberculosis strains from different subpopulations of India. Infect. Genet. Evol. 9: Aubry A, Veziris N, Cambau E, Pernot C, et al Novel gyrase mutation in quinolone resistant and hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional Analysis of mutant enzymes. Antimicrobial agents and Chemotherapy. 50: Boer M, Zanden A, Soolingen D Simultaneous detection and typing of Mycobacterium tuberculosis complex bacteria. CLI. 7. Brudey K, Driscoll J, RigoutsL,et al Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiology. 1471:6-23.
10 Cheng A, Yew W, Chan E, Chin M, et al Multiplex PCR amplimer conformation analysis of rapid detection of gyra mutations in fluroquinolone resistant Mycobacterium tuberculosis clinical isolates. Antimicrobial agents and Chemotherapy. 48: Editorial XDR-TB TB a global threat. Lancet. 368: Eldholm V, Matee M, Mfinanga S, et al A first insight into the genetic diversity of Mycobacterium tuberculosis in Dar es Salaam, Tanzania, assessed by spoligotyping. BMC Microbiology. 76 (6): Gandhi N R, Moll A, Strum W, et al Extensively drug resistant tuberculosis as a cause of death in patients co infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 368: Gupta A, Espinal M, Raviglione M Should tuberculosis programmes invest in second- line treatments for multi drug resistant tuberculosis (MDR-TB). International Journal of tubercle and lung disease. 12: Kai Man Kam, Chi Wai yip, Tze Leung Cheung, Hei Sing Tang, Oi Chi Leung, and Mei Yuk Chan Stepwise Decrease in Moxifloxacin susceptibility amongst clinical isolates of Multidrug resistant Mycobacterium tuberculosis: Correlation with Ofloxacin susceptibility. Microbial Drug Resistance. 12: Kocagoz T, Hackbarth C, Unsal I, Rosenberg H, et al Gyrase mutations in laboratory selected fluoroquinolone resistant mutants of mycobacterium tuberculosis H37Ra. Antimicrobial agents and chemotherapy. 40: LoBue Extensively drug- resistant tuberculosis. Current Opinion in Infectious Disease. 22:
11 Maus C, Plikaytis B, Shinnick T Molecular analysis of cross resistance to Capreomycin, Kanamycin, Amikacin and Viomycin in Mycobacterium tuberculosis. Antimicrobial agents and Chemotherapy. 49: Maus C, Plikaytis B, Shinnick T Mutation of tlya Confers Capreomycin Resistance in Mycobacterium tuberculosis. Antimicrobial agents and Chemotherapy. 49: Perdigao J. Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I Genetic analysis of extensively drug- resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother. 65: Rodrigues C., Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A Drug susceptibility testing of Mycobacterium tuberculosis against second line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis. 12: Ruiru S, Zhang J, Li C, Kazumi Y, Sugawara I Emergence of Ofloxacin resistance in Mycobacterium tuberculosis Clinical Isolates from China as determined by gyra mutation analysis using Denaturing High- Pressure Liquid Chromatography and DNA Sequencing. JCM.44: Shah. S, Wright. A, Bai. G, Barrera. L et al Worldwide emergence of Extensively Drug- Resistant Tuberculosis. Emerging Infectious Disease. 13: Shenai. S, Rodrigues. C and Mehta. A Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampicin, isoniazid and streptomycin in M.tuberculosis complex. Int J Infect Dis. 13:46-58.
12 Somerville W, Thibert L, Schwartzman K, Behr M Extraction of Mycobacterium tuberculosis DNA: a question of containment. Journal of clinical microbiology. 43: Somoskovi A, Parsons L, Salfinger M The molecular basis of resistance to Isoniazid, Rifampicin, and Pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2: Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Nie L, Guo A, Li C Characterization of Extensively drug resistant Mycobacterium tuberculosis clinical isolates in China. JCM. 46: Suzuki et al Detection of Kanamycin resistant Mycobacterium tuberculosis by identifying mutations in the 16S rrna gene. Journal of clinical microbiology. 36: Takiff H, Salazar L, Guerrero C, Philipp W, Huang W, et al Cloning and Nucleotide Sequence of Mycobacterium tuberculosis gyra and gyrb Genes and detection of quinolone resistance mutations. Antimicrobial agents and Chemotherapy. 38: Tsukamura M, Mizuno S Cross resistant relationships among the aminoglycoside antibiotics in Mycobacterium tuberculosis. J. Gen. Microbiol. 88: Van Soolingen D, Hermans PW, Dehaas PE, Soll DR, van EmbdenJD Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 29:
13 227 Table 1: Frequency of mutations in the various genes observed among our 150 XDR-TB isolates Drug Gene Mutation seen Amino acid change No. of isolates isoniazid katg G315C S315T 150 (100%) isoniazid inha C-15T 21 (14%) rifampicin rpob C531T S531L 146(97%) rifampicin rpob A526G H526Y 4 (3%) Fluoroquinolone i.e. ofloxacin gyra C90T A90V 37 (25%) Fluroquinolones ofloxacin and gyra T91C S91P 2 (1%) moxifloxacin Fluoroquinolone ofloxacin and gyra A94G D94G 79 (53%) moxifloxacin Fluroquinolones ofloxacin and gyra A94C D94A 18 (12%) moxifloxacin Fluoroquinolone ofloxacin and gyra G94A D94N 14 (9%) moxifloxacin Aminoglycoside i.e. kanamycin, rrs A1401G 106 (71%) amikacin Aminoglycoside i.e. kanamycin, amikacin, capreomycin rrs G1484T 42 (28%) capreomycin (n= 42) tlya+ rrs A205G K69E 13 (31%) capreomycin (n= 42) tlya+ rrs +G1484T del T at nt 674 +G1484T Frameshift 3 (7%) 228
14 229 Table 2: Spoligotyping pattern of the 150 XDR-TB isolates No Octal code Spoligotype No. of isolates Beijing CAS T EAI EAI family 35 with the % genotype Downloaded from Haarlem T on August 27, 2018 by guest 233
Drug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationCDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP)
CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP) Beverly Metchock, DrPH, D(ABMM) Mycobacteriology Laboratory Branch/Division
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationReceived 6 July 2003/Returned for modification 22 August 2003/Accepted 27 October 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2004, p. 596 601 Vol. 48, No. 2 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.2.596 601.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationExploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study
Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationUniversity of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationMGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape GWYNETH PALTROW SHAKESPEARE IN LOVE 1998 PORT
More informationMultidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
Original Article Multidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai Zarir F. Udwadia, Gautam Moharil Department of Pulmonology,
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationTHE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationEffect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
Indian J Med Res 133, May 2011, pp 535-540 Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates Mradula Singh, G.P.S. Jadaun, Ramdas, K. Srivastava,
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationMDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationPractical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationEvaluation of antimicrobial activity of Salmonella species from various antibiotic
ISSN: 2347-3215 Volume 3 Number 8 (August-2015) pp. 51-55 www.ijcrar.com Evaluation of antimicrobial activity of Salmonella species from various antibiotic Shashi P. Jambhulkar 1 * and Arun B. Ingle 2
More informationAcinetobacter Outbreaks: Experience from a Neurosurgery Critical Care Unit. Jumoke Sule Consultant Microbiologist 19 May 2010
Acinetobacter Outbreaks: Experience from a Neurosurgery Critical Care Unit Jumoke Sule Consultant Microbiologist 19 May 2010 Epidemiology of Acinetobacter spp At least 32 different species Recovered from
More informationMultidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationExtensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital
MAJOR ARTICLE Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital Christie Y. Jeon, 1,2,a Soo Hee Hwang, 5,a Jin Hong
More informationMultidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive September 2016
More informationSignificant difference in drug susceptibility distribution between Mycobacterium avium
JCM Accepts, published online ahead of print on 1 October 2014 J. Clin. Microbiol. doi:10.1128/jcm.02127-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Significant difference
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationAntimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali,
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/88030.htm Antimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali, Rwanda. Ashok
More informationXDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationCo-transfer of bla NDM-5 and mcr-1 by an IncX3 X4 hybrid plasmid in Escherichia coli 4
SUPPLEMENTARY INFORMATION ARTICLE NUMBER: 16176 DOI: 10.1038/NMICROBIOL.2016.176 Co-transfer of bla NDM-5 and mcr-1 by an IncX3 X4 hybrid plasmid in Escherichia coli 4 5 6 7 8 9 10 11 12 13 14 15 16 17
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationTuberculosis infection in an Asian elephant at a Japanese Zoo and its first treatment in Japan
Tuberculosis infection in an Asian elephant at a Japanese Zoo and its first treatment in Japan Satoshi Ishikawa, Satomi Suga, Yasuhiko Mukai Fukuyama Zoo, Hiroshima Fukuyama Zoo October 22th, 2017 Tuberculosis
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationMultidrug-Resistant Salmonella enterica in the Democratic Republic of the Congo (DRC)
Multidrug-Resistant Salmonella enterica in the Democratic Republic of the Congo (DRC) Octavie Lunguya 1, Veerle Lejon 2, Sophie Bertrand 3, Raymond Vanhoof 3, Jan Verhaegen 4, Anthony M. Smith 5, Benedikt
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationReceived 19 November 2008; returned 10 January 2009; revised 20 February 2009; accepted 24 February
Journal of Antimicrobial Chemotherapy (2009) 63, 1173 1178 doi:10.1093/jac/dkp096 Advance Access publication 28 March 2009 Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT
More informationTB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationQuality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Case studies in medicines for tuberculosis Outline: Statistics
More informationThe Honorable Thomas R. Frieden, MD, MPH Director, Centers for Disease Control and Prevention 1600 Clifton Rd, MS D-14 Atlanta, GA 30333
The Center for a Livable Future June 29, 2010 The Honorable Thomas R. Frieden, MD, MPH Director, Centers for Disease Control and Prevention 1600 Clifton Rd, MS D-14 Atlanta, GA 30333 The Honorable Anthony
More informationHouston, Texas. Methodist Hospital Research Institute, 6565 Fannin Street, Houston, Texas 77030
JCM Accepts, published online ahead of print on 8 June 2011 J. Clin. Microbiol. doi:10.1128/jcm.00231-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationPolicy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization Geneva 2008
Policy guidance on drugsusceptibility testing (DST) of secondline antituberculosis drugs World Health Organization Geneva 2008 WHO/HTM/TB/2008.392 1 World Health Organization 2008 All rights reserved.
More informationThe impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationAntimicrobial Resistance and Molecular Epidemiology of Staphylococcus aureus in Ghana
Antimicrobial Resistance and Molecular Epidemiology of Staphylococcus aureus in Ghana Beverly Egyir, PhD Noguchi Memorial Institute for Medical Research Bacteriology Department, University of Ghana Background
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationNeisseria meningitidis ANTIMICROBIAL RESISTANCE:CURRENT SITUATION IN LATIN AMERICA AND ITS CLINICAL RELEVANCE
Neisseria meningitidis ANTIMICROBIAL RESISTANCE:CURRENT SITUATION IN LATIN AMERICA AND ITS CLINICAL RELEVANCE Dra. Silvia E. González Ayala Head Professor Cátedra Infectología, Facultad Ciencias Médicas,
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationDr Dean Shuey Team Leader Health Services Development WPRO. World Health Day Antimicrobial Resistance: The Global and Regional Situation
Dr Dean Shuey Team Leader Health Services Development WPRO World Health Day 2011 Antimicrobial Resistance: The Global and Regional Situation 2 7 April 2011 World Health Day No action today, no cure tomorrow
More informationPalpasa Kansakar, Geeta Shakya, Nisha Rijal, Basudha Shrestha
In-vitro resistance of Salmonella Typhi and Paratyphi A raises concern on the use of older fluroquinolones in the empiric treatment of enteric fever in Nepal Palpasa Kansakar, Geeta Shakya, Nisha Rijal,
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationMonitoring of antimicrobial resistance in Campylobacter EURL AR activities in framework of the new EU regulation Lina Cavaco
Monitoring of antimicrobial resistance in Campylobacter EURL AR activities in framework of the new EU regulation Lina Cavaco licav@food.dtu.dk 1 DTU Food, Technical University of Denmark Outline EURL-AR
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationESCHERICHIA COLI RESISTANCE AND GUT MICROBIOTA PROFILE IN PIGS RAISED WITH DIFFERENT ANTIMICROBIAL ADMINISTRATION IN FEED
ESCHERICHIA COLI RESISTANCE AND GUT MICROBIOTA PROFILE IN PIGS RAISED WITH DIFFERENT ANTIMICROBIAL ADMINISTRATION IN FEED Caroline Pissetti 1, Jalusa Deon Kich 2, Heather K. Allen 3, Claudia Navarrete
More informationAntimicrobial Resistance Monitoring Program in Food-Producing Animals in Japan
93,0 * Antimicrobial Resistance Monitoring Program in Food-Producing Animals in Japan Tetsuo ASAI* National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries, + +/ + Tokura,
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationBacterial whole genome sequencing in clinical microbiology, infection control and public health. Julian Parkhill. FIS, Birmingham, November 2013
Bacterial whole genome sequencing in clinical microbiology, infection control and public health Julian Parkhill FIS, Birmingham, November 2013 Falling costs of genomics 2003 Cost/genome Throughput 60,000
More informationKey words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin
Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin Table 1 Detection rate of Campylobacter from stool samples taken from sporadic diarrheic patients Table 2 Detection rates of Campylobacter
More informationClinical Center of Microbiology Research, Ilam University of Medical Sciences, Ilam, Iran b
Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2014; 9(2): 162-167 ORIGINAL PAPERS Detection of Highly Ciprofloxacin Resistance Acinetobacter Baumannii Isolated from Patients
More informationβ-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018
β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus
More informationAntimicrobial Resistance Initiative
Antimicrobial Resistance Initiative Antimicrobial Resistance Initiative Resistance to antimicrobial agents has become a threat to public health all over the world. Microorganisms become resistant to antimicrobial
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationInternational Journal of Pharma and Bio Sciences ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI * PRABHAKAR C MAILAPUR, DEEPA
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationShould Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2010, p. 4765 4771 Vol. 54, No. 11 0066-4804/10/$12.00 doi:10.1128/aac.00968-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Should
More informationAntimicrobial Resistance: Do we know everything? Dr. Sid Thakur Assistant Professor Swine Health & Production CVM, NCSU
Antimicrobial Resistance: Do we know everything? Dr. Sid Thakur Assistant Professor Swine Health & Production CVM, NCSU Research Focus Antimicrobial Resistance On farm, Slaughter, Retail, Human Sample
More informationWhy Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013
Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013 Outline Drug resistance: a case study Evolution: the basics How does resistance evolve? Examples of
More informationPresence of extended spectrum β-lactamase producing Escherichia coli in
1 2 Presence of extended spectrum β-lactamase producing Escherichia coli in wild geese 3 4 5 A. Garmyn* 1, F. Haesebrouck 1, T. Hellebuyck 1, A. Smet 1, F. Pasmans 1, P. Butaye 2, A. Martel 1 6 7 8 9 10
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationMonitoring gonococcal antimicrobial susceptibility
Monitoring gonococcal antimicrobial susceptibility The rapidly changing antimicrobial susceptibility of Neisseria gonorrhoeae has created an important public health problem. Because of widespread resistance
More informationDrug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016
Drug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016 Drug- Resistant TB: De1initions Mono- resistant: Resistance to a single drug Poly-
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.80.2.143 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2017;80:143-152 Current Status of Fluoroquinolone Use for Treatment of Tuberculosis
More informationRandall Singer, DVM, MPVM, PhD
ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What
More informationEU Research on Antimicrobial drug resistance Anna Lönnroth Sjödén Unit Infectious Diseases, Directorate Health DG Research European Commission
1 EU Research on Antimicrobial drug resistance Anna Lönnroth Sjödén Unit Infectious Diseases, Directorate Health DG Research European Commission PathoGenomics ERA-NET, Brussels, 23 September 2010 2 EU
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More information